ArticleJournal of orthopaedic translation2019
Safety and efficacy of cyclooxygenase-2 inhibition for treatment of primary hypertrophic osteoarthropathy: A single-arm intervention trial.
Article in Journal of orthopaedic translation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Two cases of primary hypertrophic osteoarthropathy caused by HPGD variants: a case report and literature review.BMC pediatrics · 2025Pooled it
- Clinical Determinants and Bone Metabolic Correlates of 24-h Urinary PGE2 and PGEM Excretion in Chinese Adults: A Multicenter Cross-Sectional Study.Biomedicines · 2026Article
- Elevated calcitonin gene-related peptide expression through prostaglandin E2-EP4 receptor pathway in promoting proliferative periosteum formation in primary hypertrophic osteoarthropathy.Journal of orthopaedic translation · 2026Article
- Acquired digital clubbing in 2 healthy young men: The incomplete form of pachydermoperiostosis (primary hypertrophic osteoarthropathy).JAAD case reports · 2026Article
- BiallelicFrontiers in endocrinology · 2026Article
- Targeting Metabolomics in Primary Hypertrophic Osteoarthropathy: Uncovering Novel Insights into Disease Pathogenesis.The Journal of clinical endocrinology and metabolism · 2025Article
- A Loss-of-Function Variant Causing Primary Autosomal Recessive Hypertrophic Osteoarthropathy.Cureus · 2025Article
- [Rare cause of massive joint effusions].Zeitschrift fur Rheumatologie · 2025Article
- Distinct features of three clinical subtypes in 533 patients with primary hypertrophic osteoarthropathy.Orphanet journal of rare diseases · 2025Article
- Giant cell carcinoma of the lung with hypertrophic pulmonary osteoarthropathy as a paraneoplastic syndrome: a case report.General thoracic and cardiovascular surgery cases · 2023Article
- Primary hypertrophic osteoarthropathy: genetics, clinical features and management.Frontiers in endocrinology · 2023Review
- Digital clubbing, joint pain, and skin changes in a young man: primary hypertrophic osteoarthropathy.Clinical rheumatology · 2022Article
- What is the appropriate treatment strategy for cryptogenic multifocal ulcerative stenosing enteritis? A single-center experience from China.Frontiers in medicine · 2022Article
- Etoricoxib as a treatment of choice for patients withFrontiers in genetics · 2022Article
- Clinical and biochemical characteristics of 12 Chinese primary hypertrophic osteoarthropathy patients with HPGD mutations.International journal of biological sciences · 2022Article
- Nanoparticle-Cartilage Interaction: Pathology-Based Intra-articular Drug Delivery for Osteoarthritis Therapy.Nano-micro letters · 2021Review
- Article
- Characterization of Mineral and Bone Metabolism Biomarkers in a Chinese Consanguineous Twin Family with Primary Hypertrophic Osteoarthropathy.International journal of endocrinology · 2020Article
- The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation.Endocrine connections · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundPrimary hypertrophic osteoarthropathy (PHO) is a rare disease involving joint, bone and skin. Two underlying genes responsible for this disease-hydroxyprostaglandin dehydrogenase (
methodsWe recruited patients presenting to Peking Union Medical Hospital between January 2009 and December 2016 who were diagnosed with PHO. Participants were given the COX-2 inhibitor etoricoxib (60 mg once daily) and followed up for 9 months. Gene analysis was performed at baseline. The following data were collected at baseline and during treatment: visual analogue score (VAS), volume of the distal middle finger (VDMF), knee joint circumference (KJC), serum and urinary levels of prostaglandin E2 (PGE2) and PGE metabolite (PGE-M) and serum levels of inflammatory markers.
resultsA total of 27 patients were recruited, including seven patients with PHO type I (PHOAR1) carrying
conclusionsWe found COX-2 inhibitor to be safe and effective for the treatment of PHO in our cohort. THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: The underlying genes responsible for PHO suggest COX inhibitor as potential therapy, and our study demonstrates the efficacy and safety of this treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.